Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer

Paclitaxel is a chemotherapeutic agent that acts as an inhibitor of cellular mitosis and has been widely used in the treatment of triple-negative breast cancer (TNBC). However, paclitaxel resistance is one of the major reasons that contribute to the high failure rates of chemotherapy and the relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tao, Zhang, Tingrong, Zhang, Yao, Zhou, Bin, Lu, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986375/
https://www.ncbi.nlm.nih.gov/pubmed/35399640
http://dx.doi.org/10.1155/2022/6019975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986375/
https://www.ncbi.nlm.nih.gov/pubmed/35399640
http://dx.doi.org/10.1155/2022/6019975

Ejemplares similares